Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print Protein that provides innate defense against HIV could lead to new treatments

Protein that provides innate defense against HIV could lead to new treatments

May 27, 2008

By identifying a protein that restricts the release of HIV-1 virus from human cells, scientists believe they may be closer to identifying new approaches to treatment. The research is published in the advance online edition of Nature Medicine.

Scientists have known that most human cells contain a factor that regulates the release of virus particles, but until now they have been uncertain about the factor's identity. Now a research team from Emory University School of Medicine, Vanderbilt University School of Medicine, and Mayo Medical School has identified CAML (calcium-modulating cyclophilin ligand) as the cellular protein that inhibits the release of HIV particles.




CAML works by inhibiting a very late step in the virus lifecycle, leading to the retention of HIV particles on the membrane of the cell. The virus has developed a means of counteracting CAML, through the action of the viral Vpu protein. When Vpu is absent, HIV particles don't detach from the plasma membrane and instead accumulate by a protein tether at the cell surface.

When the research team depleted CAML in human cells in the laboratory, they found that Vpu was no longer required for the efficient exit of HIV-1 particles from the cell. When they expressed CAML in cell types that normally allow particles to exit freely, the particles remained attached to the cell surface.

"This research is important because it identifies CAML as an innate defense mechanism against HIV," says senior author Paul Spearman, professor of pediatrics (infectious diseases) at Emory University School of Medicine. "We are continuing to work on the mechanism that Vpu uses to counteract CAML and on defining exactly how CAML leads to virus particle retention on the infected cell membrane. We hope this will lead us to new treatments."

Emory University



Related HIV-1 Virus Current Events and HIV-1 Virus News Articles HIV-1 Virus Current Events and HIV-1 Virus News RSS HIV-1 Virus Current Events and HIV-1 Virus News RSS
Study offers insights into failed HIV-1 vaccine trial
Following the disbandment of the STEP trial to test the efficacy of the Merck HIV-1 vaccine candidate in 2007, the leading explanation for why the vaccine was ineffective - and may have even increased susceptibility to acquiring the virus - centered on the hypothesis that high levels of baseline Ad5-specific neutralizing antibodies may have increased HIV-1 acquisition among the study subjects who received the vaccine by increasing Ad5-specific CD4+ T-cells that were susceptible to HIV-1 infection.

MU Researcher Refining Synthetic Molecules to Prevent HIV Resistance
Evolving HIV viral strains and the adverse side effects associated with long-term exposure to current treatments propel scientists to continue exploring alternative HIV treatments.

T cell-based HIV vaccine candidate demonstrates positive results
The question of whether or not to continue to pursue the development of T-cell-based HIV-1 vaccines has been a source of controversy following last year's widely publicized failure of the field's most promising candidate, a vaccine developed by Merck known as V520.

Wild gorillas carriers of a SIV virus close to the AIDS virus
In 2005, 40.3 million people in the world, including 25.8 million in Sub-Saharan Africa, were living with HIV. The question of the origin of HIV-1, responsible for the AIDS pandemic, has been stimulating the scientific community for many years.

Defense peptide found in primates may block some human HIV transmissions
As primates evolved 7 million years ago, the more advanced species stopped making a protein that University of Central Florida researchers believe can effectively block the HIV-1 virus from entering and infecting blood cells.

Meth Promotes Spread of Virus in HIV-Infected Users
Researchers at the University at Buffalo have presented the first evidence that the addictive drug methamphetamine, or meth, also commonly known as "speed" or "crystal," increases production of a docking protein that promotes the spread of the HIV-1 virus in infected users.

Researchers discover how leukaemia virus spreads through the body
Researchers from Imperial College London, University of Oxford, Kagoshima University (Japan) and University of the Ryukyus (Japan) have discovered the mechanism by which human T-lymphotropic virus type 1 (HTLV-1), the virus which causes adult T-cell leukaemia, spreads through the body.

Timely Antiretroviral Therapy Essential For Best Prognosis In People With HIV-1 Infection (p 119)
Authors of an international study in this week's issue of THE LANCET highlight how timely treatment with highly-active antiretroviral therapy (HAART) can substantially improve the three-year prognosis for people with HIV-1 infection. HAART became widespread in more-developed countries in 1996. However, there is insufficient data from individual studies to estimate the prognosis of people with HIV-1 infection starting HAART. The ART Cohort Collaboration, led by Matthias Egger from the University of Bern, Switzerland, was established to fill this knowledge gap. The investigators analysed data on over 12,000 adult patients from 13 prospective studies from Europe and North America. The patients

Second Stage of HIV Vaccine Trial Begins In London and Oxford
A new phase of the world`s first clinical trial to test a vaccine candidate for one of the most prevalent HIV strains affecting Africa starts today (Thursday 4 April 2002) in London and Oxford. This expands the ongoing trials in Oxford and Nairobi which aim to harness the ability of the body`s own immune system to fight disease. The first volunteers on the London arm of the trial were vaccinated today. Volunteers are randomised into groups, which will receive various combinations of the two vaccine components or a placebo at differing intervals. This is predominantly a safety study but the information collected may help establish optimum dosage, how many booster injections to give and a vacc
More HIV-1 Virus Current Events and HIV-1 Virus News Articles
  Antiviral activity of Rwandan medicinal plants against human immunodeficiency virus type-1 (HIV-1).: An article from: Phytomedicine: International Journal of Phytotherapy & Phytopharmacology
by P. Cos (Author), N. Hermans (Author), T. De Bruyne (Author), S. Apers (Author), J.B. Sindambiwe (Author), M. Witvrouw (Author), E. De Clercq (Author), D. Vanden Berghe (Author), L. Pieters (Author), A.J. Vlietinck (Author)

This digital document is an article from Phytomedicine: International Journal of Phytotherapy & Phytopharmacology, published by Urban & Fischer Verlag on January 1, 2002. The length of the article is 3764 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Antiviral activity of Rwandan medicinal plants against human immunodeficiency virus type-1 (HIV-1).
Author: P. Cos
Publication: Phytomedicine: International Journal of Phytotherapy & Phytopharmacology (Refereed)
Date: January 1, 2002
Publisher: Urban & Fischer Verlag
Volume: 9 Issue: 1 Page:...

Home Access HIV - 1 Express Test System - 1 ea

Home Access HIV - 1 Express Test System - 1 ea
by Home Access

Next Day Results*
Contains one single-use sample collection kit

  Neutral Disinfectant Cleaner, Kills Over 120 Viruses, Including Hepatitis, Hiv, Flu, German Measles, Herpes Simplex and Many More. Cleans and Disinfects!. 1 Galllon Concentrate Makes 65 Gallons of Ready to Use Product
by Misco

This Gallon Cleaner is very Concentrated. 1 Gallon Makes 65 Gallons Of Ready To Use Product. This disinfectant is Great for our whole house! Use it i n your Kitchen, Bathroom tile floors, Stainless Steel and much more. It Kills Over 120 Viruses.

HIV (Human Immunodeficiency Virus) GIANTMicrobes Original

HIV (Human Immunodeficiency Virus) GIANTMicrobes Original
by GIANTMicrobes, Inc.

HIV (Human Immunodeficiency Virus) GIANTMicrobes Original - H.I.V. kills CD4 cells, or T-helper cells. Once the immune system is compromised, a person develops AIDS (acquired immuno-deficiency syndrome). H.I.V. is most commonly transmitted by sexual contact with an infected person. Insect bites and sweat carry almost no risk of transmission. Studies show that drying H.I.V. infected fluids can reduce viral presence by 90-99%. There is no vaccine for H.I.V. and no cure for AIDS. This item is a GIANTmicrobes(R) Original (5-7" plush doll). GIANTMicrobes Original - GIANTMicrobes by Drew Oliver! [Product ID: GM-HIV1] [SKU: GMUS-PD-0400] [UPC: 890242000001]

Translation Regulation of the Human Immunodeficiency  Virus type 1: A study of HIV-1 protein synthesis initiation

Translation Regulation of the Human Immunodeficiency Virus type 1: A study of HIV-1 protein synthesis initiation
by Ann Brasey (Author)

Over the last 50 years, the human immunodeficiency virus (HIV) has swept across the six continents, claiming several million lives yearly. Despite sustained intense research efforts, there is still no cure for HIV. For billions of years, viruses evolved strategies to enter and take control of organisms to generate progeny viruses, including means of hijacking the cellular protein synthesis machinery. Understanding these mechanisms opens a unique window of opportunity: that of eventually being able to specifically inhibit virus protein production and thus put a stop to virus replication. In this work, HIV-1 protein synthesis was studied, uncovering the presence of an internal ribosome entry site (IRES) in the genetic code of HIV-1. IRESes are structures...

HIV-1: Molecular Biology and Pathogenesis: Viral Mechanisms, Volume 55, Second Edition (Advances in Pharmacology)

HIV-1: Molecular Biology and Pathogenesis: Viral Mechanisms, Volume 55, Second Edition (Advances in Pharmacology)
by Kuan-Teh Jeang (Editor), J. Thomas August (Editor), Ferid Murad (Editor)

This volume covers the latest advances in the mechanisms of pathogenesis of the HIV-1 virus on target cells. Its companion volume, Advances in Pharmacology 56, shows how new developments in understanding the virus translate to the clinical setting.

  Progress reports in the battle against acquired immune deficiency syndrome. (toll-free AIDS information, zidovudine for pregnant women, antigen test for HIV-1): An article from: FDA Consumer
by U.S. Government Printing Office (Publisher)

This digital document is an article from FDA Consumer, published by U.S. Government Printing Office on October 1, 1989. The length of the article is 880 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Progress reports in the battle against acquired immune deficiency syndrome. (toll-free AIDS information, zidovudine for pregnant women, antigen test for HIV-1)
Publication: FDA Consumer (Magazine/Journal)
Date: October 1, 1989
Publisher: U.S. Government Printing Office
Volume: v23 Issue: n8 Page: p5(1)

Distributed by Thomson...

  HIV-1 infection and drug-abuse in India--an emerging challenge.(Clinical report): An article from: American Journal of Infectious Diseases
by Mahendra Kumar (Author), Adarsh M. Kumar (Author), Raymond Ownby (Author), Deborah L. Jones (Author), Drenna Waldrop-Valverde (Author)

This digital document is an article from American Journal of Infectious Diseases, published by Thomson Gale on October 1, 2007. The length of the article is 3083 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: HIV-1 infection and drug-abuse in India--an emerging challenge.(Clinical report)
Author: Mahendra Kumar
Publication: American Journal of Infectious Diseases (Magazine/Journal)
Date: October 1, 2007
Publisher: Thomson Gale
Volume: 3 Issue: 4 Page: 191(4)

Article Type: Clinical report

Distributed by Thomson...

  New findings in preventing HIV-1 infection.(Upfront): An article from: Journal of Dental Hygiene
by Heather Shirley (Author)

This digital document is an article from Journal of Dental Hygiene, published by American Dental Hygienists' Association on September 22, 2003. The length of the article is 2432 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: New findings in preventing HIV-1 infection.(Upfront)
Author: Heather Shirley
Publication: Journal of Dental Hygiene (Refereed)
Date: September 22, 2003
Publisher: American Dental Hygienists' Association
Volume: 77 Issue: 4 Page: 214(2)

Distributed by Thomson...

  The prozone phenomenon with syphilis and HIV-1 co-infection.(Case Report): An article from: Southern Medical Journal
by Gregory Smith (Author), Robert P. Holman (Author)

This digital document is an article from Southern Medical Journal, published by Southern Medical Association on April 1, 2004. The length of the article is 2439 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: The prozone phenomenon with syphilis and HIV-1 co-infection.(Case Report)
Author: Gregory Smith
Publication: Southern Medical Journal (Refereed)
Date: April 1, 2004
Publisher: Southern Medical Association
Volume: 97 Issue: 4 Page: 379(4)

Distributed by Thomson...

© 2009 BrightSurf.com